What did @kmartfit actually say?
The creator's core argument is that once-weekly testosterone injections produce unstable blood levels because "testosterone-cypionate only has a 3.5 day half-life." His solution: split the same dose into two injections per week. He also calls any doctor prescribing once-weekly injections a sign of a "terrible clinic" that doesn't understand pharmacokinetics. Then he pivots to selling a $169/month telehealth service via comment DMs.
That's worth separating into two conversations: the science of injection frequency, and the marketing claim that once-weekly dosing is universally wrong. They're not the same thing.
Does the science back this up?
Partially, yes. The half-life claim is roughly accurate, and the logic around smoother levels is supported by data. But calling once-weekly dosing a "red flag" overstates the evidence considerably.
Testosterone cypionate has a reported half-life of approximately 8 days, not 3.5 days. The 3.5-day figure is closer to testosterone enanthate's half-life, which is typically cited at 4-5 days. This is not a trivial mix-up when your entire argument rests on half-life math. That said, the underlying pharmacokinetic principle is real. More frequent injections do reduce peak-to-trough fluctuations. Ramasamy et al. (2014, Journal of Urology) documented that patients on more frequent, smaller doses reported more consistent symptom control. And Dobs et al. (1999, Clinical Endocrinology) showed that intramuscular testosterone produces supraphysiologic peaks followed by sub-therapeutic troughs with less frequent dosing. So the direction of his argument is correct even if the numbers aren't quite right.
What did they get wrong (or right)?
He got the concept right but mangled the specifics, and then oversold the conclusion.
The half-life error matters. Testosterone cypionate's half-life is approximately 8 days according to prescribing literature, which actually makes once-weekly dosing more defensible than his argument implies, not less. If you're using 3.5 days as your justification for twice-weekly injections, you've built a correct recommendation on an incorrect foundation.
The claim that once-weekly dosing means you won't "see the benefits" is also too strong. Many patients maintain therapeutic levels on once-weekly protocols. The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) acknowledge both once-weekly and twice-weekly injection schedules as acceptable, individualized based on patient labs and symptoms. Calling a guideline-supported protocol a "red flag" is not a clinical opinion, it's a sales tactic.
What he got right: splitting doses is a legitimate, often preferable approach for patients who are sensitive to hormonal fluctuations. That's real. The problem is wrapping a reasonable clinical preference in absolutist language to funnel viewers toward a DM-based clinic referral.
What should you actually know?
Injection frequency is genuinely a clinical decision, not a one-size verdict. Here's what the evidence actually supports.
- Testosterone cypionate's half-life is approximately 8 days, not 3.5 days. That figure likely refers to enanthate or was misremembered.
- Twice-weekly injections do reduce peak-to-trough variability. For patients experiencing mood swings, energy crashes, or libido dips mid-week, splitting doses is a reasonable clinical adjustment supported by pharmacokinetic data.
- Once-weekly injections are not inherently wrong. They remain an accepted protocol in clinical guidelines when labs show adequate trough levels and the patient is symptom-stable.
- The American Urological Association and Endocrine Society both emphasize individualizing TRT protocols based on bloodwork and symptom response, not a universal frequency rule.
- Any creator recommending you switch clinics via a comment DM while citing inaccurate half-life numbers is not your endocrinologist. Get your protocol decisions from a licensed provider who can see your actual lab values.
Is the clinic pitch a problem?
Yes, and it's worth naming directly. The video follows a well-worn influencer-to-telehealth pipeline: create urgency ("your doctor is failing you"), offer a simple fix (twice-weekly injections), then monetize the anxiety with a referral link. The $169/month price point and "no side effects" promise deserve serious skepticism. No TRT protocol comes with a guarantee of no side effects. Erythrocytosis, testicular atrophy, and cardiovascular considerations are real risks that require monitoring, not a sales pitch. "You'll feel all the benefits with no side effects" is not a clinical claim. It's an ad.